Literature DB >> 9741329

Monitoring of bone metastases.

R E Coleman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9741329     DOI： 10.1016/s0959-8049(97)10134-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  10 in total

1.  Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients.

Authors:  G L Smith; A P Doherty; L M Banks; J Dutton; L W Hanham; T J Christmas; R J Epstein
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy.

Authors:  Makito Miyake; Takuya Owari; Kiyohide Fujimoto
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

4.  Assessment of the effects of zoledronic Acid therapy on bone metabolic indicators in hormone-resistant prostate cancer patients with bone metastatasis.

Authors:  Abdullah Demirtas; Nurettin Sahin; Mehmet Caniklioglu; Mustafa Kula; Oguz Ekmekcioglu; Atila Tatlisen
Journal:  ISRN Urol       Date:  2011-05-04

5.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.

Authors:  J Vinholes; R Coleman; D Lacombe; C Rose; M Tubiana-Hulin; P Bastit; J Wildiers; J Michel; R Leonard; J Nortier; F Mignolet; J Ford
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Risk of metastasis among rib abnormalities on bone scans in breast cancer patients.

Authors:  Qin Li; Zhiqiang Chen; Yansheng Zhao; Xiuqing Li; Hong Pan; Tiansong Xia; Lin Chen; Zhaoqiang Xu; Wenbin Zhou; Xiaoan Liu
Journal:  Sci Rep       Date:  2015-05-05       Impact factor: 4.379

8.  Serum Alkaline Phosphatase in Cryptogenic Stroke Cases with Active Cancer.

Authors:  Tesseki Izumi; Hitoki Nanaura; Naohiko Iguchi; Maki Ozaki; Kazuma Sugie
Journal:  Intern Med       Date:  2022-03-01       Impact factor: 1.271

9.  Weekly epirubicin in patients with hormone-resistant prostate cancer.

Authors:  R Petrioli; A I Fiaschi; D Pozzessere; S Messinese; M Sabatino; S Marsili; P Correale; A Manganelli; F Salvestrini; G Francini
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

10.  Diagnostic and prognostic validity of serum bone turnover markers in bone metastatic non-small cell lung cancer patients.

Authors:  Zhiyu Wang; Yaohong Lu; Dan Qiao; Xiaoting Wen; Hui Zhao; Yang Yao
Journal:  J Bone Oncol       Date:  2015-09-30       Impact factor: 4.072
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.